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Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, United KingdomBackground. Partial Risk Adjustment in Surgery
(PRAiS), a risk model for 30-day mortality after children’s
heart surgery, has been used by the UK National
Congenital Heart Disease Audit to report expected risk-
adjusted survival since 2013. This study aimed to
improve the model by incorporating additional comor-
bidity and diagnostic information.
Methods. The model development dataset was all pro-
cedures performed between 2009 and 2014 in all UK and
Ireland congenital cardiac centers. The outcome measure
was death within each 30-day surgical episode. Model
development followed an iterative process of clinical dis-
cussion and development and assessment of models using
logistic regression under 25 3 5 cross-validation. Perfor-
mance was measured using Akaike information criterion,
the area under the receiver-operating characteristic curve
(AUC), and calibration. The ﬁnalmodel was assessed in an
external 2014 to 2015 validation dataset.
Results. The development dataset comprised 21,838
30-day surgical episodes, with 539 deaths (mortality, 2.5%).
The validation dataset comprised 4,207 episodes,Accepted for publication Dec 12, 2016.
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(http://creativecommons.org/licenses/by/4.0/).with 97 deaths (mortality, 2.3%). The updated risk model
included 15 procedural, 11 diagnostic, and 4 comorbidity
groupings, and nonlinear functions of age and weight.
Performance under cross-validation was: median AUC of
0.83 (range, 0.82 to 0.83), median calibration slope and
intercept of 0.92 (range, 0.64 to 1.25) and –0.23 (range, –1.08
to 0.85) respectively. In the validationdataset, theAUCwas
0.86 (95% conﬁdence interval [CI], 0.82 to 0.89), and the
calibration slope and intercept were 1.01 (95% CI, 0.83 to
1.18) and 0.11 (95%CI, –0.45 to 0.67), respectively, showing
excellent performance.
Conclusions. A more sophisticated PRAiS2 risk model
for UK use was developed with additional comorbidity
and diagnostic information, alongside age and weight as
nonlinear variables.
(Ann Thorac Surg 2017;-:-–-)
 2017 The Authors. Published by Elsevier Inc. on behalf
of The Society of Thoracic Surgeons. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).pproximately 3,500 children under 16 years of ageAhave heart surgery each year in the United Kingdom
[1] and since 2000 all cardiac centers have contributed
procedure data to the National Congenital Heart Disease
Audit (NCHDA). Center-speciﬁc mortality outcomes for
individual procedures have been published online since
2007 by the NCHDA [2].
With the accumulation of registry based data,
consensus-based risk stratiﬁcation methods for pediatric
cardiac surgery, such as the Risk Adjusted classiﬁcationfor Congenital Heart Surgery (RACHS-1) [3] and Aristotle
[4] methods, have given way to empirical approaches
including the Society of Thoracic Surgeons–European
Association of Cardiothoracic Surgery (STS-EACTS)
score [5]. The Partial Risk Adjustment in Surgery (PRAiS)
risk model for 30-day mortality after pediatric cardiac
surgery was developed in 2011, using 10 years of UK
audit data [6, 7] alongside accompanying software toThe Supplemental Materials can be viewed in the
online version of this article [http://dx.doi.org/10.1016/
j.athoracsur.2016.12.014] at http://www.annalsthoracic
surgery.org.
iety of Thoracic Surgeons.
0003-4975/$36.00
http://dx.doi.org/10.1016/j.athoracsur.2016.12.014
2 ROGERS ET AL Ann Thorac Surg
THE UK PRAiS2 MODEL 2017;-:-–-implement it for routine monitoring [8], and has been
used by the NCHDA since 2013.
The PRAiS model incorporated information about
procedure (29 categories), cardiac diagnosis (3 risk cate-
gories), number of functioning ventricles, age category
(neonate, infant, child), age, and weight as continuous
variables, as well as presence of a non–Down syndrome
comorbidity and whether surgery was performed on
cardiopulmonary bypass. As the PRAiS model began to
be used to monitor outcomes, data quality for information
previously collected but not actively used (eg, comor-
bidity and diagnosis codes) improved rapidly.
This study uses recent NCHDA data to improve the
PRAiS model by incorporating more detailed informa-
tion about comorbid conditions, acuity, and diagnosis.
In this paper, the original model will be referred to as
the PRAiS1 model and the new model as the PRAiS2
model.Material and Methods
Data
NCHDA data are subject to external validation and sur-
vival status is independently veriﬁed for patients resident
in England or Wales by the Health and Social Care In-
formation Centre.
The development dataset consisted of all pediatric
cardiac procedures performed in the United Kingdom
and Ireland from April 2009 to March 2014. Records were
excluded if the patient was over 16 years of age; the
procedure was noncardiac, nonsurgical, or minor; or it
was performed at 1 small-volume center that ceased pe-
diatric cardiac surgery in 2010.
In February 2016, the NCHDA provided a further year
of procedure data for April 2014 to March 2015: this was
used as an external validation dataset. The ﬁnal model
was recalibrated on all data from 2009 to 2015.
The unit of analysis was a 30-day surgical episode [6, 7].
For each patient an episode started with their ﬁrst sur-
gical procedure. Any further surgical procedures that the
same patient underwent within 30 days of this ﬁrst pro-
cedure were not included. The next surgical procedure
recorded for the same patient more than 30 days after the
ﬁrst surgical procedure was treated as the start of a new,
independent 30-day episode. The outcome measure was
death within each 30-day surgical episode. Where the life
status at 30 days could not be determined, discharge
status prior to 30 days was used.
Data Cleaning
Duplicate records and inconsistencies in age or life status
within or across records relating to the same patient were
identiﬁed, removed, or resolved.
Episodes in the development dataset with an absolute
weight-for-age Z-score of 5 or over or with a weight
judged to be infeasible by a clinician or a missing weight
were assigned the mean weight-for-age. To mimic pro-
spective use, no adjustments of weight were made when
an episode was being used for validation.Risk Factors Considered
PROCEDURES. A Speciﬁc Procedure hierarchical algorithm
was developed by the NCHDA to sort submitted indi-
vidual European Pediatric Cardiac Code (EPCC) [9] codes
into a Speciﬁc Procedure category. We used the Speciﬁc
Procedure Algorithm Coding v5.05 from May 2016 [10],
which includes 49 Speciﬁc Procedures.
In the PRAiS1 model, only bypass and nonbypass
surgical procedures were included. For the PRAiS2 model
the hybrid procedure for hypoplastic left heart syndrome
(HLHS) [11] was also incorporated.
DIAGNOSIS. A scheme that maps the individual EPCC
diagnosis codes recorded for each episode to 1 of 29
hierarchical diagnostic categories was used [12, 13] (see
Supplemental Material 1 for details). An increase in the
number of diagnostic groupings from the 3 broad groups
used in the PRAiS1 model [6] was explored.
A surgical episode was determined to relate to a patient
witha functionallyuniventricularheart if theyhadadiagnosis
or procedure code suggesting single-ventricle physiology.
COMORBIDITY. Each episode can have several different
EPCC comorbidity codes recorded. Possible ways to
include more comorbidity information were explored as
discussed in detail in Brown and colleagues [14].
AGE AND WEIGHT. The association of both age and weight
with the log odds of mortality is nonlinear. The PRAiS1
model used a continuous linear weight and age and
neonate, infant and child age bands as categorical risk
factors [6]. However, this resulted in unrealistic jumps in
predicted risk at age band boundaries. To better capture
this nonlinearity and explore any interaction between age
and weight, we considered age and weight categories in
combination with continuous age, weight, and weight-
for-age Z-scores similarly to the STS model [15], cubic
splines [16], and fractional polynomials [17].
Model Development Strategy
Asrawmortality rate is low (<3%), there is apractical limit to
how many parameters can be reasonably included in an
empirical risk model. A common rule of thumb is that
overﬁtting is alleviated if thenumberofdeaths in thedataset
is at least 10 times larger than thenumberofparameters [18].
This gave a practical limit of about 40 parameters that could
be included in the PRAiS2 model, necessitating a trade-off
between adding comorbidity and diagnostic information
and reducing Speciﬁc Procedure information, particularly
given the increase in the number of individual procedure
categories included in the Speciﬁc Procedure algorithm,
including several lower volume categories.
An expert advisory panel from 5 hospitals comprising 3
surgeons (V.T., D.A., D.J.B.), 2 cardiologists (K.E., R.C.F.),
2 intensivists (K.L.B., S.T.), and 2 data management
experts (T.W., J.S.) was assembled to consider the relative
importance of comorbidities and potential trade-offs in
included risk factors.
Analysis
Groupings of comorbidity codes were determined using
the clinical and coding expertise of the panel, informed by
Fig 1. Inclusions and exclusions from the development dataset. (NCHDA ¼ National Congenital Heart Disease Audit.)
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comorbidity groupings with mortality [14].
Classiﬁcation and regression tree analysis [19] was used
to deﬁne initial broader groupings of procedure and
diagnostic categories, taking into account patient age and
observed mortality. These groups were adjusted itera-
tively after consultation with the clinical expert panel and
testing of the performance of the resultant risk models
under cross-validation. The expert panel provided advice
on procedures and diagnoses where the observed mor-
tality was not considered representative of the risk, or
where procedures or diagnoses that were qualitatively
different should not be combined in a single group.
Multiple logistic regression was used within the Stata
statistical software package (StataCorp 2013, Release 13,
College Station, TX).
Comparison of candidate models was performed
within the development dataset using the area under the
receiver-operating characteristic curve (AUC) and Akaike
information criterion.
Fivefold cross-validation repeated 25 times (25 5 cross-
validation) was then carried out [20], with the data splits
stratiﬁed by year and unit to ensure a representative case
mix. Themedian and range of the AUC over the 25 repeats
of the cross-validation was calculated [21]. The calibration
slope (b) and intercept (a) were estimated in each of the 125test sets [22], and the median and range were calculated. b
gives an indication of whether the model is underﬁtting or
overﬁtting the data, and a indicates whether the model is
underpredicting or overpredicting deaths. If a model is
perfectly calibrated, b ¼ 1 and a ¼ 0 [23].
A comparison was also made to the PRAiS1 model
recalibrated on the development dataset to ensure that
improvements in model performance were achieved.
Finally, any episodes that had particularly large
leverage or inﬂuence [16] were investigated to see
whether they were genuine outliers or data errors.
Performance of the ﬁnal selected model is reported as
the median and range of the AUC, calibration slope, and
calibration intercept over the cross-validated test sets and
the AUC, calibration slope, and intercept are reported
with 95% conﬁdence intervals (CI) in the external vali-
dation set.Results
The cleaned development dataset comprised 21,838
30-day surgical episodes, of which 539 resulted in death
within 30 days (mortality rate, 2.5%). Figure 1 gives a
summary of the records excluded from the development
dataset.
Table 1. Speciﬁc Procedures Included in Each Speciﬁc Procedure Group, With Their Respective Frequencies and 30-Day Mortalities
Speciﬁc Procedure Groups Frequency 30-Day Mortality
Group 1 633 (2.9) 11.1
Norwood Procedure (Stage 1) 589 (2.7) 10.7
HLHS hybrid approach 44 (0.2) 15.9
Group 2 414 (1.9) 7.2
TAPVC repair þ arterial shunt 10 (0.0) 60.0
Truncus and interruption repair 15 (0.1) 6.7
Truncus arteriosus repair 190 (0.9) 5.3
Interrupted aortic arch repair 118 (0.5) 5.1
Arterial switch þ aortic arch obstruction repair (with-without VSD closure) 81 (0.4) 8.6
Group 3 760 (3.5) 7.8
Arterial shunt 760 (3.5) 7.8
Group 4 1,171 (5.4) 3.9
Repair of total anomalous pulmonary venous connection 329 (1.5) 5.2
Arterial switch þ VSD closure 311 (1.4) 2.6
Isolated pulmonary artery band 531 (2.4) 4.0
Group 5 1,885 (8.6) 4.1
PDA ligation (surgical) 1,885 (8.6) 4.1
Group 6 1,996 (9.1) 1.2
Arterial switch (for isolated transposition) 724 (3.3) 1.5
Isolated coarctation/hypoplastic aortic arch repair 1,236 (5.7) 1.0
Aortopulmonary window repair 36 (0.2) 0.0
Group 7 667 (3.1) 4.6
Senning or Mustard procedure 16 (0.1) 12.5
Ross-Konno procedure 69 (0.3) 2.9
Mitral valve replacement 164 (0.8) 3.7
Pulmonary vein stenosis procedure 96 (0.4) 6.3
Pulmonary atresia VSD repair 201 (0.9) 4.5
Tetralogy with absent pulmonary valve repair 48 (0.2) 4.2
Unifocalization procedure (with/without shunt) 73 (0.3) 5.5
Group 8 1,508 (6.9) 2.7
Heart transplant 152 (0.7) 3.3
Tricuspid valve replacement 17 (0.1) 5.9
Aortic valve repair 292 (1.3) 2.1
Pulmonary valve replacement 328 (1.5) 1.8
Aortic root replacement (not Ross) 59 (0.3) 3.4
Cardiac conduit replacement 167 (0.8) 1.8
Isolated RV to PA conduit construction 400 (1.8) 3.3
Tricuspid valve repair 93 (0.4) 4.3
Group 9 369 (1.7) 3.5
Multiple VSD closure 59 (0.3) 1.7
Atrioventricular septal defect and tetralogy repair 50 (0.2) 2.0
Cor triatriatum repair 54 (0.2) 5.6
Supravalvar aortic stenosis repair 102 (0.5) 3.9
Rastelli-REV procedure 104 (0.5) 3.8
Group 10 1,156 (5.3) 1.7
Bidirectional cavopulmonary shunt 1,156 (5.3) 1.7
Group 11 889 (4.1) 1.0
Atrioventricular septal defect (complete) repair 889 (4.1) 1.0
Group 12 989 (4.5) 1.0
Fontan procedure 989 (4.5) 1.0
(Continued)
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Table 1. Continued
Speciﬁc Procedure Groups Frequency 30-Day Mortality
Group 13 1,264 (5.8) 0.4
Aortic valve replacement: Ross 151 (0.7) 0.7
Subvalvar aortic stenosis repair 609 (2.8) 0.3
Mitral valve repair 235 (1.1) 0.4
Sinus venosus ASD and/or PAPVC repair 269 (1.2) 0.4
Group 14 2,152 (9.9) 0.6
Atrioventricular septal defect (partial) repair 396 (1.8) 0.5
Tetralogy of Fallot–type DORV repair 1,521 (7.0) 0.7
Vascular ring procedure 235 (1.1) 0.4
Group 15 2,868 (13.1) 0.1
Anomalous coronary artery repair 94 (0.4) 0.0
Aortic valve replacement: non-Ross 93 (0.4) 0.0
ASD repair 941 (4.3) 0.0
VSD repair 1,740 (8.0) 0.2
No speciﬁc procedure group 3,117 (14.3) 2.9
No speciﬁc procedure 3,117 (14.3) 2.9
Values are n (%) or %.
ASD ¼ atrial septal defect; DORV ¼ double outlet right ventricle; HLHS ¼ hypoplastic left heart syndrome; PA ¼ pulmonary artery;
PDA ¼ patent ductus arteriosus; PAPVC ¼ partial anomalous pulmonary venous connection; REV ¼ reparation a letage ventriculaire; RV ¼
right ventricle; TAPVC ¼ total anomalous pulmonary venous connection; VSD ¼ ventricular septal defect.
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0.6% of records were missing a relevant ﬁeld.
Of the ﬁnal 21,838 episodes, 5 episodes had their
weights adjusted from grams to kilograms and 33 epi-
sodes with anomalous or missing weight were assigned
the mean weight for their age.
For 3,165 episodes (14.5%), the discharge status prior to
30 days was used to generate outcome as certiﬁed life
status was unavailable (overwhelmingly for overseas
patients lacking a UK national health identiﬁer).
The validation dataset comprised 4,207 episodes with
97 deaths (mortality rate, 2.3%). To mimic prospective
use, no adjustments to missing or anomalous weights
were made. For 724 episodes (17.2%), the discharge status
prior to 30 days was used as a proxy for 30-day life status.
New Comorbidity, Procedure, and Diagnosis Groups
The comorbidity factors included in the model were:
congenital comorbidity; acquired comorbidity; severity of
illness; and additional cardiac risk factor.
The 49 speciﬁc procedures were combined into 15
procedure groups as well as a no Speciﬁc Procedure
category; these are shown in Table 1. The 29 diagnosis
categories were combined into 11 diagnosis groups; these
are shown in Table 2.
The groups were determined on a basis of complexity,
risk, age, any association between procedures and diag-
nosis, and the clinical validity of the groups. For instance,
arterial shunts, which are performed on a wide variety of
patients, were retained as a separate group.
The PRAiS2 model includes similar additional risk
factors to the STS model variables [24] of noncardiac
congenital anatomic abnormality, chromosomal abnor-
mality or syndrome, and preoperative factors. Thetreatment of procedural and diagnostic information in
the 2 models differs, with the STS model including a
separate intercept parameter for each combination of
age group and primary procedure, and no diagnostic
information. The PRAiS2 procedural and diagnostic
groups were determined accounting for interactions
between procedures, diagnoses, risk and age, and clin-
ical validity.
Other Risk Factors
The HLHS hybrid approach procedures were included in
the nonbypass procedure category.
Fractional polynomials of the form axþ b ﬃﬃxp were best
able to capture the relationship of both age and weight
with mortality, and were much preferred by the clinical
expert panel to avoid artifactual changes in estimates of
risk at age or weight category boundaries. Similarly to the
STS model, age-for-weight Z-scores did not improve the
model.
Mortality has been falling in the United Kingdom and
Ireland [25], with particular reduction post-2012. Similar
to the PRAiS1 model, a binary post-2012 epoch variable
was included.
Once the ﬁnal model risk factors had been chosen,
shrinkage [22] was considered. There was little indication
of overﬁtting and shrinkage did not signiﬁcantly improve
calibration under cross-validation.
Final Risk Model
The ﬁnal risk model was a logistic regression model with
the following variables: age; weight; procedure group;
diagnosis group; procedure type; univentricular heart
indicator; congenital comorbidity indicator, acquired co-
morbidity indicator; severity of illness indicator; additional
Table 2. Diagnoses Included in Each Diagnosis Group, With Their Respective Frequencies and 30-Day Mortality Rates
Diagnosis Groups Frequency
30-Day
Mortality
Group 1 2,034 (9.3) 6.4
HLHS 1,401 (6.4) 6.5
Truncus arteriousus 398 (1.8) 4.8
Pulmonary atresia and IVS 235 (1.1) 8.9
Group 2 2,569 (11.8) 4.6
Functionally UVH 1,436 (6.6) 4.5
Pulmonary atresia and VSD 1,133 (5.2) 4.7
Group 3 1,380 (6.3) 3.3
TGA þ VSD/DORV-TGA 1,171 (5.4) 3.3
Interrupted aortic arch 209 (1.0) 2.9
Group 4 1,724 (7.9) 4.1
PDA 1,724 (7.9) 4.1
Group 5 1,869 (8.6) 2.4
Miscellaneous primary congenital diagnosis 1,248 (5.7) 2.2
Tricuspid valve abnormality (including Ebstein’s) 219 (1.0) 2.7
TAPVC 302 (1.4) 3.0
No diagnosis given 100 (0.5) 2.0
Group 6 447 (2.0) 2.5
Acquired 447 (2.0) 2.5
Group 7 3,711 (17.0) 1.5
AVSD 1,737 (8.0) 2.0
Fallot/DORV Fallot 1,974 (9.0) 1.1
Group 8 1,273 (5.8) 1.6
Aortic valve stenosis (isolated) 517 (2.4) 1.9
Mitral valve abnormality 496 (2.3) 1.0
Miscellaneous congenital terms 260 (1.2) 1.9
Group 9 544 (2.5) 2.0
TGA þ IVS 544 (2.5) 2.0
Group 10 2,022 (9.3) 0.7
Aortic arch obstruction þ VSD/ASD 1,582 (7.2) 0.8
Pulmonary stenosis 440 (2.0) 0.5
Group 11 4,265 (19.5) 0.4
Subaortic stenosis (isolated) 265 (1.2) 0.0
Aortic regurgitation 217 (1.0) 0.0
VSD 2,389 (10.9) 0.7
ASD 1,269 (5.8) 0.1
Arrhythmia 125 (0.6) 0.8
Values are n (%) or %.
ASD ¼ atrial septal defect; AVSD ¼ atrioventricular septal defect; DORV ¼ double outlet right ventricle; HLHS ¼ hypoplastic left heart
syndrome; IVS ¼ intact ventricular septum; PDA ¼ patent ductus arteriosus; TAPVC ¼ total anomalous pulmonary venous connection;
TGA ¼ transposition of the great arteries; UVH ¼ univentricular heart; VSD ¼ ventricular septal defect.
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The frequency and 30-day mortality rates in the develop-
ment datasets for the categorical risk factors included in
the model are shown in Table 3. As the Speciﬁc Procedure
and diagnosis groups are grouped by age and similarity as
well as risk, the odds ratios compared to the reference
group are not informative and so are not included.
Under cross-validation, the model had a median AUC
of 0.83 (range, 0.82 to 0.83), showing excellent discrimi-
nation. There was only slight evidence of overﬁtting, with
a median calibration slope of 0.92 (range, 0.64 to 1.25) and
median calibration intercept of –0.23 (range, 1.08 to 0.85;perfect calibration slope ¼ 1 and intercept ¼ 0), indicating
slight underprediction.
The recalibrated PRAiS1 model had a median AUC of
0.80 (range, 0.80 to 0.81), and a median calibration slope
and intercept of 0.90 (range, 0.63 to 1.31) and –0.29 (range,
–1.15 to 1.06), respectively, and so was outperformed by
the PRAiS2 model across all measures.
In the external validation set, there were 97 observed
deaths in the test set compared with 89 predicted. The
AUC was 0.86 (95% CI, 0.82 to 0.89) (Fig 2) and the cali-
bration slope and intercept were 1.01 (95% CI, 0.83, 1.18)
and 0.11 (95% CI, –0.45 to 0.67), respectively. The model
Table 3. The Frequency, Mortality, OR, and p Value for the Final Categorical Risk Factors
Risk Factor
Records
(N ¼ 21,838) Deaths (%) OR (95% CI) p Value
Speciﬁc procedure group
Group 1 633 70 (11.1) . .
Group 2 414 30 (7.2) . .
Group 3 760 59 (7.8) . .
Group 4 1,171 46 (3.9) . .
Group 5 1,885 78 (4.1) . .
Group 6 1,996 23 (1.2) . .
Group 7 667 31 (4.6) . .
Group 8 1,508 40 (2.7) . .
Group 9 369 13 (3.5) . .
Group 10 1,156 20 (1.7) . .
Group 11 889 9 (1.0) . .
Group 12 989 10 (1.0) . .
Group 13 1,264 5 (0.4) . .
Group 14 2,152 13 (0.6) . .
Group 15 2,868 3 (0.1) . .
No speciﬁc procedure 3,117 89 (2.9) . .
Diagnosis group . .
Group 1 2,034 131 (6.4) . .
Group 2 2,569 117 (4.6) . .
Group 3 1,380 45 (3.3) . .
Group 4 1,724 70 (4.1) . .
Group 5 1,869 45 (2.4) . .
Group 6 447 11 (2.5) . .
Group 7 3,711 56 (1.5) . .
Group 8 1,273 20 (1.6) . .
Group 9 544 11 (2.0) . .
Group 10 2,022 15 (0.7) . .
Group 11 4,265 18 (0.4) . .
Procedure type
Nonbypass 5,032 176 (3.5) Reference .
Bypass 16,806 363 (2.2) 1.5 (1.1–2.1) 0.013
UVH status
Not UVH 18,101 352 (1.9) Reference .
UVH 3,737 187 (5.0) 1.9 (1.4–2.7) <0.001
Severity of illness (acuity)
No indication of severe illness 19,578 369 (1.9) Reference .
Indication of severe illness 2,260 170 (7.5) 1.7 (1.4–2.2) <0.001
Acquired cardiac risk factor
No indication of acquired cardiac risk factor 20,785 483 (2.3) Reference .
Indication of acquired cardiac risk factor 1,053 56 (5.3) 2.2 (1.6–3.0) <0.001
Acquired comorbidity
No indication of acquired comorbidity 20,584 458 (2.2) Reference .
Indication of acquired comorbidity 1,254 81 (6.5) 2.0 (1.5–2.6) <0.001
Congenital comorbidity
No indication of congenital comorbidity 19,393 449 (2.3) Reference .
Indication of a congenital comorbidity 2,445 90 (3.7) 1.5 (1.2–1.9) 0.001
Procedure year
Pre-2013 16,259 429 (2.6) Reference .
2013 onward 5,579 110 (2.0) 0.7 (0.6–0.9) 0.003
CI ¼ conﬁdence interval; OR ¼ odds ratio; UVH ¼ univentricular heart.
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Fig 2. The receiver-operating characteristic curve of the model tested
on the validation dataset (area under the receiver-operating
characteristic curve ¼ 0.86).
8 ROGERS ET AL Ann Thorac Surg
THE UK PRAiS2 MODEL 2017;-:-–-showed excellent performance, comparing well with the
STS score (AUC, 0.86) [15].
The ﬁnal model was recalibrated on all of the data from
2009 to 2015. Full details can be found in Supplemental
Material 2.Comment
This study has produced an improved PRAiS risk model
by using more information about comorbidity and diag-
nosis while reducing the total number of model
parameters from 38 to 36. Two independent risk models
(STS and PRAiS) using different national datasets have
now resulted in similar risk factors and a similar meth-
odology of close iterative interaction between analysts
and experts from the clinical community.
The clinical validity of the risk factors to be included in
the PRAiS2 model was discussed in considerable detail by
the expert panel, as were known case mix differences
between centers. In particular, the clinical experience of
the panel added value to the empirical evidence to deﬁne
the ﬁnal comorbidity and additional risk factors and the
ﬁnal broader Speciﬁc Procedure and diagnosis groupings.
The close involvement of the expert panel representing
many hospitals and different specialties was very suc-
cessful, allowed careful consideration of how individual
codes have been, and will be used by centers in practice
and built trust in the ﬁnal model within the clinical
community.
Despite the excellent performance of the PRAiS2
model, there is 1 case mix feature present within the
model that needs highlighting: risk for the HLHS hybrid
procedure, generally performed on the sickest patients, is
underpredicted. Of the 60 HLHS hybrid procedures in
the 2009 to 2015 data, there were 10 observed deaths but
only 6 predicted deaths. This additional risk cannot yet be
well captured in the PRAiS2 model due to low case vol-
ume. Additionally, this procedure has predominantly
been performed at 1 center, which could therefore beunfairly affected in the prospective national audit. The
expert panel recommended including HLHS hybrid
procedures within the PRAiS2 model despite these issues
as this procedure is expected to become more common. It
has been proposed to the NCHDA steering committee
that the PRAiS2 model for future national audit is run
twice on data including and excluding hybrid HLHS
procedures in turn so that this effect can be accounted for.
As this procedure becomes more common, the PRAiS2
model will be recalibrated to better reﬂect this particular
risk.
This case mix feature highlights the importance of the
continual process of use and collaborative development
of this and similar models, as the quality and quantity of
the data available increases and as clinical practice
evolves.
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